AKCEA THERAPEUTICS, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|
| Revenue | $163.8M | $17.1M | $43.4M | $0 | $0 |
| Operating income | $26.2M | −$30.3M | −$59.9M | −$16.0M | −$61.4M |
| Net income | $27.2M | −$29.6M | −$60.4M | −$16.0M | −$61.4M |
| Total assets | $599.3M | $365.3M | $268.8M | $10.7M | — |
| Total liabilities | $56.2M | $88.5M | $89.2M | $28.4M | — |
| Equity | $543.0M | $276.7M | $179.6M | −$17.7M | $55.3M |
| EPS (diluted) | — | — | — | — | — |
| Shares out. | 89.4M | 66.6M | 66.5M | 0 | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- 16.0%
- Net margin
- 16.6%
- Return on equity
- 5.0%
- Return on assets
- 4.5%
- Return on capital (ROCE)
- 4.7%
- Liabilities / assets
- 9.4%
- Debt / equity
- 0.10×
- Book value / share
- $6.07
- Revenue growth (YoY)
- 857.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 12.79safe
- Accruals / assets
- −32.8%clean
- Piotroski F-Score
- 8/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 13, 2020
- Entered a material agreement · Amended charter or bylaws · Other material eventAug 31, 2020
- Results of operationsAug 4, 2020
- Entered a material agreement · Director / officer changeJul 9, 2020
- Director / officer changeJun 19, 2020
- Director / officer changeMay 18, 2020
- Results of operationsMay 5, 2020
- Director / officer changeApr 29, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ANov 10, 2020
- 15-12BOct 23, 2020
- 4FORM 4 SUBMISSIONOct 14, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020
- 4FORM 4 SUBMISSIONOct 13, 2020